Recently, Huang et al. demonstrated that in various epithelial prostate cancer cell lines, the induced overexpression of MAO-B attenuated their proliferative, migratory, and invasive potential, while treatment with selegiline reversed these beneficial effects. The gene discussed is MAOB; the disease is prostate carcinoma.